CANCER BIOMARKERS AND HEALTH SYSTEMS: THE DYNAMICS OF A SCIENTIFICALLY BASED TRANSFORMATION

Cancer biomarkers are molecular markers that play a crucial role in the diagnosis, treatment, and monitoring of cancer. These markers enable more accurate patient classification and the development of personalized treatment strategies. The effect of genetic differences on the disease process necessitates the use of biomarkers in clinical decision-making. Advanced analysis technologies and multi-biomarker panels have increased diagnostic accuracy and facilitated the monitoring of treatment responses. Integrating biomarkers into healthcare policies expands opportunities for early diagnosis, enables more effective management of treatment processes, and increases the cost-effectiveness of healthcare services. Advanced technologies, such as artificial intelligence, nanotechnology, and big data analysis, enhance the sensitivity and specificity of biomarkers, thereby strengthening the success of precision medicine applications. These innovations enable the development of personalized treatment approaches and contribute to the sustainability of healthcare systems. In this context, the integration of biomarkers into health policies expands early diagnostic opportunities, improves service quality, and contributes to the creation of sustainable health systems. It is critically important for policymakers to consider scientific accuracy, patient safety, and ethical principles when evaluating these technological advances in order to effectively manage future health issues.